Psychostimulants for cancer-related fatigue

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 8, 2010, Pages 933-942

  Breitbart, William ^a,b   Alici, Yesne ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Central Regional Hospital   (United States)

Author keywords

Cancer related fatigue; Fatigue; Psychostimulants; Wakefulness promoting agents

Indexed keywords

ARMODAFINIL; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DEXTRO THREO METHYLPHENIDATE; METHYLPHENIDATE; MODAFINIL; PEMOLINE; UNCLASSIFIED DRUG;

AGITATION; ANOREXIA; ANXIETY DISORDER; BACKACHE; BIPOLAR DEPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; NARCOLEPSY; NAUSEA; NERVOUSNESS; QUALITY OF LIFE; REVIEW; RHINITIS; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; VOMITING; XEROSTOMIA;

EID: 77957362534     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0068     Document Type: Review

References (35)

1. Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J Natl Compr Canc Netw 2007;5:1081-1091. (Pubitemid 350247714)
2. Minton O, Richardson A, Sharpe M, et al A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155-1166.
3. Berger AM, Abernethy AP, Atkinson A, et al. NCCN clinical practice guidelines in oncology: cancer-related fatigue. Version 1, 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/fatigue.pdf. Accessed June 1, 2010.
4. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003;64(Suppl 11):14-18.
5. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001;161:411-420.
6. Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989;50:5-8.
7. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436-440. (Pubitemid 30452211)
8. Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989;4:3-6. (Pubitemid 19093472)
9. Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001;18:187-192.
10. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 2000;8:385-397.
11. Connors CK, Eisenberg L. The effects of methylphenidate on symptomatology and learning in disturbed children. Am J Psychiatry 1963;120:458-464
12. Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002;16:261-263. (Pubitemid 34537672)
13. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;29:E85-90.
14. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006;14:210-215.
15. Johnson RL, Block I, Gold MA, et al. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology 2009; in press.
16. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer a preliminary report. J Clin Oncol 2003;21:4439-4443.
17. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:2073-2078. (Pubitemid 46622117)
18. Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2010; in press.
19. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 2010;116:766-774.
20. Lasheen W, Walsh D, Mahmoud F, et al. Methylphenidate side effects in advanced cancer: a retrospective analysis. Am J Hosp Palliat Care 2010;27:16-23.
21. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009;38:650-662.
22. Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008;16:577-583.
23. Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d- threomethylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007;69:1496-1501.
24. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436-440.
25. Auret KA, Schug SA, Bremner AP, Bulsara M. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage 2009;37:613-621.
26. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130-136.
27. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006;11:93-102. (Pubitemid 43306504)
28. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-1249.
29. Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann Pharmacother 2009;43:721-725.
30. MacAllister WS, Krupp LB. Multiple sclerosis-related fatigue. Phys Med Rehabil Clin N Am 2005;16:483-502.
31. Morrow GR, Ryan J, Kohli S, et al. Modafinil for persistent post-treatment fatigue: an open label study of 82 women with breast cancer [abstract 11-070]. Support Care Cancer 2006;14:Abstract 619.
32. Kaleita TA, Wellisch DK, Graham CA, et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 1503.
33. Blackhall L, Petroni G, Shu J, et al. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 2009;12:433-439.
34. Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 2009;23:325-331.
35. Morrow GR, Jean-Pierre P, Roscoe JA, et al. A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: a URCC CCOP study (abstract). J Clin Oncol 2008;26(Suppl 1):Abstract 9512.